
Opinion|Videos|July 16, 2026
Navigating Dosing Frequency With Revumenib and Ziftomenib
Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.
Episodes in this series

In this episode, Ali discusses the clinical implications of twice-daily versus once-daily dosing in patients with relapsed/refractory AML who are frequently monitored in clinic. He explains how half-life differences impact differentiation syndrome management, toxicity offset, and practical adherence counseling.
Latest CME
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
3
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5






































































































